

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-19. (Canceled).

20. (Currently amended) A method of screening for a compound that suppresses cell growth of a breast cancer cell ~~for treating or preventing breast cancer~~, said method comprising the steps of:

- a) contacting a test compound with T-LAK cell-originated protein kinase a polypeptide encoded by a polynucleotide of the gene of BRC No. 456;
- b) detecting the binding activity between the kinase polypeptide and the test compound; and
- c) selecting the test compound that binds to the kinase; polypeptide
- d) contacting the test compound selected in step (c) with a breast cancer cell; and
- e) further selecting the test compound that suppresses cell growth of a breast cancer cell, as compared to cell growth in the absence of the test compound.

21-22. (Canceled).

23. (Currently amended) A method of screening for a compound that suppresses cell growth of a breast cancer cell ~~for treating or preventing breast cancer~~, said method comprising the steps of:

- a) contacting a test compound with T-LAK cell-originated protein kinase a polypeptide encoded by a polynucleotide of the gene of BRC No. 456;
- b) detecting the kinase activity of the kinase polypeptide of step (a);
- c) selecting the test compound that suppresses the kinase activity of the T-LAK cell-originated protein kinase polypeptide encoded by the polynucleotide of the gene

~~of BRC No. 456~~ as compared to the kinase activity of said kinase polypeptide detected in the absence of the test compound;

- d) contacting the test compound selected in step (c) with a breast cancer cell; and  
e)d) further selecting ~~from the test compound selected in step (e)~~, the test compound that suppresses the cell growth of a breast cancer cell as compared to cell growth detected in the absence of the test compound;  
~~wherein said test compound is useful for treating or preventing breast cancer.~~

24. (Canceled).

25. (Currently amended) The method of claim 20, wherein said breast cancer is invasive ductal carcinoma (IDC), said method comprises the steps of:

- a) contacting a test compound with T-LAK cell-originated protein kinase a polypeptide encoded by a polynucleotide of the gene of BRC No. 456;  
b) detecting the binding activity between the kinase polypeptide and the test compound; and  
c) selecting the test compound that binds to the kinase polypeptide;  
d) contacting the test compound selected in step (c) with an IDC cell; and  
e) further selecting the test compound that suppresses the cell growth of an IDC cell, as compared to the cell growth detected in the absence of the test compound.

26-27. (Canceled).

28. (Currently amended) The method of claim 23, wherein said breast cancer is IDC and said method comprises the steps of:

- a) contacting a test compound with T-LAK cell-originated protein kinase a polypeptide encoded by a polynucleotide of the gene of BRC No. 456;  
b) detecting the kinase activity of the kinase polypeptide of step (a);  
c) selecting the test compound that suppresses the kinase activity of the T-LAK cell-originated protein kinase polypeptide encoded by the polynucleotide of the gene

~~of BRC No. 456~~, as compared to the kinase activity of said kinase polypeptide  
detected in the absence of the test compound;

- d) contacting the test compound selected in step (c) with an IDC cell;and  
e)d) further selecting, from the test compound selected in step (c), the test compound  
that suppresses the cell growth of an IDC cell as compared to cell growth detected  
in the absence of the test compound;  
~~wherein said test compound is useful for treating or preventing IDC.~~

29-99. (Canceled).